Genmab A/S
NASDAQ:GMABBiotechnology
-$0.12 today
- Market cap
- $31.43B
- Beta
- 0.68
- P/E (TTM)
- 18.7
- EPS (TTM)
- $13.36
Volume 2.96M
Average 1.85M
GMAB Total Debt
Short-term and long-term borrowings combined.
Genmab A/SNASDAQ: GMAB
Total Debt · Q2 FY2026 · quarter ended Jun 2026
Total debt rises 3463.6% from a year ago
Total debt stood at $5.27B at the end of Q2 FY2026, up 3463.6% from a year earlier and down 1.5% from the prior quarter. Over 3 fiscal years it compounded at +108.7% a year.
Context
- Total debt amounted to 42.1% of total assets at the end of Q2 FY2026, up 39.8 pp from a year earlier.
- Total debt increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +3463.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
Mixed currencies · from the balance sheet
- Latest · FY2025
- 5.43B USD
- Year-over-year change
- —
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.43B | — |
| FY2024 | 2024-12-31 | 1.03B | +33.6% |
| FY2023 | 2023-12-31 | 770M | +29.0% |
| FY2022 | 2022-12-31 | 597M | +40.5% |
| FY2021 | 2021-12-31 | 425M | — |
Total Debt vs competitors
How GMAB compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +3463.6% is the highest of 11, against a peer median of -8.8%.
- Total debt amounts to 42.1% of total assets for GMAB, versus a peer median of 5.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $5.27B USD | +3463.6% | +108.7% | 42.1% | |
| Jun 2026 | €315.97M EUR | +17.2% | +8.0% | 1.6% | |
| Sep 2026 | $167.4M USD | -59.2% | +13.3% | 10.0% | |
| Jul 2026 | $165.93M USD | -7.7% | -3.1% | 6.7% | |
| Mar 2026 | $116.67M USD | -74.1% | +50.1% | 40.0% | |
| Jun 2026 | $114M USD | +4.6% | -2.3% | 12.3% | |
| Sep 2026 | $45.21M USD | -13.9% | -17.2% | 4.6% | |
| Jun 2026 | $38.27M USD | -9.8% | +18.8% | 0.5% | |
| Mar 2026 | $36.51M USD | -2.6% | +45.3% | 16.8% | |
| Mar 2026 | $5.22M USD | -47.7% | -20.6% | 2.9% | |
| Mar 2026 | $2.93M USD | +5.8% | +15.4% | 2.0% | |
| Peer median (excluding GMAB) | — | -8.8% | +10.6% | 5.6% | |
Competitors are the stored peer set for GMAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 · DKK | FY2022 Dec 2022 · DKK | FY2023 Dec 2023 · DKK | FY2024 Dec 2024 · DKK | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Cash & Equivalents | 8.96B | 9.89B | 14.87B | 9.86B | 1.71B |
| Short-term Investments | 10.38B | 12.43B | 13.27B | 11.24B | 0 |
| Net Receivables | 3.37B | 5.71B | 4.95B | 6.69B | 1.15B |
| Inventory | 0 | 0 | 57M | 62M | 17.96M |
| Other Current Assets | 31M | 182M | 0 | 0 | 3 |
| Total Current Assets | 22.74B | 28.22B | 33.14B | 27.85B | 2.88B |
| Property, Plant & Equipment (Net) | 975M | 1.32B | 1.64B | 263.83M | 279.36M |
| Goodwill | 0 | 0 | 0 | 2.54B | 354.19M |
| Intangible Assets | 254M | 146M | 101M | 12.34B | 9.1B |
| Long-term Investments | 371M | 133M | 134M | 228M | 58.87M |
| Tax Assets | 0 | 0 | 212M | 126.68M | 170.61M |
| Other Non-current Assets | 291M | 300M | 62M | 2.46B | 4 |
| Total Non-current Assets | 1.89B | 1.9B | 2.15B | 17.96B | 9.97B |
| Total Assets | 24.63B | 30.12B | 35.29B | 45.81B | 12.84B |
| Account Payables | 350M | 0 | 0 | 0 | 1.07B |
| Short-term Debt | 0 | 0 | 0 | 0 | 273M |
| Tax Payables | 0 | 0 | 54M | 1.71B | 0 |
| Deferred Revenue | 0 | 0 | 33M | 24M | 23.95M |
| Other Current Liabilities | 860M | 1.75B | 0 | 0 | (663.92K) |
| Total Current Liabilities | 1.57B | 1.82B | 2.48B | 5.31B | 1.42B |
| Long-term Debt | 0 | 0 | 0 | 0 | 5B |
| Deferred Tax Liabilities | 0 | 0 | 0 | 2.36B | 363.17M |
| Deferred Revenue (Non-current) | 0 | 0 | 480M | 480M | 94.78M |
| Other Non-current Liabilities | 500M | 491M | 35M | 30M | 5M |
| Total Non-current Liabilities | 863M | 1.01B | 1.2B | 3.81B | 5.59B |
| Total Liabilities | 2.43B | 2.84B | 3.68B | 9.11B | 7.01B |
| Common Stock | 66M | 66M | 66M | 66M | 9.98M |
| Retained Earnings | 10.02B | 14.81B | 19.02B | 23.55B | 4.09B |
| Accumulated OCI | 81M | 98M | 60M | 490M | (180.59M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 22.2B | 27.28B | 31.61B | 36.7B | 5.83B |
| Total Debt | 425M | 597M | 770M | 1.03B | 5.43B |
| Net Debt | (8.53B) | (9.3B) | (14.1B) | (8.83B) | 3.71B |
Genmab A/S
NASDAQ:GMAB
Intrinsic Alpha fair value
Locked
Current Price
$50.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.